Optos announced a £10 million collaboration with scientists and clinicians from NHS Greater Glasgow and Clyde, and the Universities of Kent and Strathclyde, for the development of a new imaging technology that could allow earlier detection of sight threatening eye disease, according to a company news release.
An initial £1.1 million study, funded by Innovate UK and Optos, will develop a laser based technology to monitor the function of the cells in the eye. The enhanced technology is expected to detect and monitor eye disease at a very early stage, enabling earlier intervention and better treatment regimes. The first clinical studies will focus on the leading causes of blindness – age-related macular degeneration, glaucoma, and diabetic retinopathy – and are expected to be completed in the first half of 2017. If successful, a further £9 million will be invested to develop a fully licensed medical device for the NHS by 2018.
"We are delighted to play a key role in this important collaboration with the NHS supported by clinical research. Blindness is a largely preventable disease burden that we believe can be eased through earlier detection. Optos strives to create the tools for professionals at the forefront of eye care and disease management," Roy Davis, CEO of Optos, said in the news release. "This initiative demonstrates not only the importance of early intervention, but how innovation and investment through collaboration can translate into better patient outcomes.”